NASDAQ:ADVM

Adverum Biotechnologies Stock Forecast, Price & News

$8.86
-0.54 (-5.74 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.58
Now: $8.86
$9.38
50-Day Range
$9.02
MA: $10.52
$13.32
52-Week Range
$8.75
Now: $8.86
$26.98
Volume1.08 million shs
Average Volume834,394 shs
Market Capitalization$866.47 million
P/E RatioN/A
Dividend YieldN/A
Beta1.72
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Adverum Biotechnologies logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADVM
CUSIPN/A
Phone650-656-9323
Employees167
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$250,000.00
Book Value$2.71 per share

Profitability

Net Income$-64,490,000.00

Miscellaneous

Market Cap$866.47 million
Next Earnings Date5/27/2021 (Estimated)
OptionableOptionable

Headlines

Adverum Biotechnologies (NASDAQ:ADVM) Shares Gap Down to $9.40
April 17, 2021 |  americanbankingnews.com
Adverum Biotechnologies (NASDAQ:ADVM) Shares Down 4.8%
April 9, 2021 |  americanbankingnews.com
Adverum Biotechnologies (NASDAQ:ADVM) Shares Gap Up to $10.08
April 5, 2021 |  americanbankingnews.com
Adverum Biotechnologies (NASDAQ:ADVM) Shares Gap Down to $9.43
March 30, 2021 |  americanbankingnews.com
See More Headlines

MarketRank

Overall MarketRank

1.49 out of 5 stars

Medical Sector

530th out of 2,024 stocks

Biological Products, Except Diagnostic Industry

75th out of 177 stocks

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$8.86
-0.54 (-5.74 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ADVM News and Ratings via Email

Sign-up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Adverum Biotechnologies (NASDAQ:ADVM) Frequently Asked Questions

Is Adverum Biotechnologies a buy right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adverum Biotechnologies in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Adverum Biotechnologies stock.
View analyst ratings for Adverum Biotechnologies
or view top-rated stocks.

What stocks does MarketBeat like better than Adverum Biotechnologies?

Wall Street analysts have given Adverum Biotechnologies a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Adverum Biotechnologies wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Adverum Biotechnologies' next earnings date?

Adverum Biotechnologies is scheduled to release its next quarterly earnings announcement on Thursday, May 27th 2021.
View our earnings forecast for Adverum Biotechnologies
.

How were Adverum Biotechnologies' earnings last quarter?

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) released its quarterly earnings results on Sunday, February, 28th. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by $0.07.
View Adverum Biotechnologies' earnings history
.

How has Adverum Biotechnologies' stock been impacted by COVID-19?

Adverum Biotechnologies' stock was trading at $9.26 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ADVM stock has decreased by 4.3% and is now trading at $8.86.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ADVM?

10 Wall Street analysts have issued 1-year target prices for Adverum Biotechnologies' stock. Their forecasts range from $13.00 to $36.00. On average, they anticipate Adverum Biotechnologies' stock price to reach $23.50 in the next year. This suggests a possible upside of 165.2% from the stock's current price.
View analysts' price targets for Adverum Biotechnologies
or view top-rated stocks among Wall Street analysts.

Who are Adverum Biotechnologies' key executives?

Adverum Biotechnologies' management team includes the following people:
  • Ms. Leone D. Patterson M.B.A., Pres, CFO, Principal Financial Officer & Principal Accounting Officer (Age 58, Pay $874k)
  • Dr. Aaron Osborne, Chief Medical Officer (Age 47, Pay $695.38k)
  • Dr. Laurent Fischer, CEO & Director (Age 57)
  • Ms. Angela Thedinga M.B.A., M.P.H., Chief Technology Officer (Age 39)
  • Ms. Myesha Lacy, VP of Investor Relations & Corp. Communications
  • Mr. Peter Soparkar J.D., Chief Legal Officer & Corp. Sec. (Age 50)
  • Ms. Dena House, VP of HR
  • Mr. Christopher J. DeRespino, Chief Bus. Officer

What is Laurent Fischer, M.D.'s approval rating as Adverum Biotechnologies' CEO?

3 employees have rated Adverum Biotechnologies CEO Laurent Fischer, M.D. on Glassdoor.com. Laurent Fischer, M.D. has an approval rating of 72% among Adverum Biotechnologies' employees.

Who are some of Adverum Biotechnologies' key competitors?

What other stocks do shareholders of Adverum Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adverum Biotechnologies investors own include CTI BioPharma (CTIC), California Resources (CRC), CA (CA), BlackRock (BLK), Amarin (AMRN), Endologix (ELGX), Immunomedics (IMMU), Advanced Micro Devices (AMD), Aurinia Pharmaceuticals (AUPH) and Genocea Biosciences (GNCA).

What is Adverum Biotechnologies' stock symbol?

Adverum Biotechnologies trades on the NASDAQ under the ticker symbol "ADVM."

How do I buy shares of Adverum Biotechnologies?

Shares of ADVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adverum Biotechnologies' stock price today?

One share of ADVM stock can currently be purchased for approximately $8.86.

How much money does Adverum Biotechnologies make?

Adverum Biotechnologies has a market capitalization of $866.47 million and generates $250,000.00 in revenue each year. The biotechnology company earns $-64,490,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis.

How many employees does Adverum Biotechnologies have?

Adverum Biotechnologies employs 167 workers across the globe.

What is Adverum Biotechnologies' official website?

The official website for Adverum Biotechnologies is www.adverum.com.

Where are Adverum Biotechnologies' headquarters?

Adverum Biotechnologies is headquartered at 800 Saginaw Drive, Redwood City CA, 94063.

How can I contact Adverum Biotechnologies?

Adverum Biotechnologies' mailing address is 800 Saginaw Drive, Redwood City CA, 94063. The biotechnology company can be reached via phone at 650-656-9323 or via email at [email protected]


This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.